Buprenorphine and Naloxone: Suboxone, Opioid Treatment and Withdrawal

The combination is used in treatment of opioid dependence or opioid use disorder, within a broader plan of care. Buprenorphine is a partial opioid agonist that can reduce withdrawal and craving. Naloxone is included to discourage misuse by injection. Suboxone and Zubsolv are brand examples, with formulations and age indications varying between countries. [1] [2]

Ask which product you have and why it was chosen. The two numbers printed on a packet refer to two active ingredients, not two doses to take separately. A clinician or pharmacist should explain the preparation and schedule. Do not infer the correct amount from a previous single-ingredient buprenorphine prescription.

When the medicine is used through the intended oral-mucosal route, buprenorphine provides the principal opioid-treatment effect. The naloxone component is intended to deter injection misuse, which can trigger severe withdrawal and other harm. It does not make the medicine impossible to misuse or incapable of causing overdose. [1]

Do not inject, snort or otherwise alter the route. Ask the clinician about concerns rather than experimenting to see how the ingredients behave. A combination formulation is a safety design, not a guarantee that every use is safe. Treatment still requires appropriate prescribing, secure storage and review of other substances.

A Suboxone film or Zubsolv tablet is not a rescue medicine for someone who is unconscious or breathing abnormally. The naloxone contained in it does not replace a separately available overdose-reversal spray or injection. A person receiving the combination should still discuss access to rescue medication and emergency training. [3]

For suspected opioid overdose, call local emergency services and use available rescue naloxone according to its instructions. Follow dispatcher advice for breathing support or CPR and stay with the person. Do not put a combination tablet or film into the mouth of an unresponsive person. A temporary improvement does not remove the need for emergency assessment.

The timing and method of starting treatment depend on recent opioid exposure and the clinical situation. Starting at the wrong point can cause precipitated withdrawal, a sudden worsening of symptoms. The prescriber must assess the opioid involved, other medicines and the treatment setting rather than relying on a universal waiting interval. [4]

Give an accurate account of recent prescribed and nonprescribed opioids, including methadone or treatment received elsewhere. Explain uncertainty about the contents of a product rather than guessing. Do not alternate leftover opioids and combination films to create your own initiation plan. Ask who will respond if symptoms become difficult and what should prompt urgent medical assessment.

Buprenorphine-naloxone can be involved in a withdrawal plan, but it also has an important ongoing treatment role. Medication treatment for opioid use disorder reduces important health risks, and a short withdrawal episode alone is not the recommended endpoint. A person may benefit from maintenance rather than repeated cycles of detoxification and return to use. [5]

Ask whether the proposed course is intended as short-term withdrawal management or continuing treatment, and why. A residential discharge date should not automatically become the last day of an effective prescription. Discuss the next supply, clinician and follow-up before leaving. Recovery can include long-term medication; it does not require stopping treatment merely to meet a medication-free ideal.

Regular treatment can lead to physical dependence, meaning withdrawal may occur if it is stopped abruptly. Dependence during appropriate treatment is not identical to uncontrolled, harmful opioid use. The distinction matters because the medicine may be helping reduce that harmful pattern even while the body has adapted to it. [3]

Discuss concerns about dependence openly. Ask how the team evaluates benefit, control over use and adverse effects. Do not let pressure from others lead to an abrupt stop without review. Equally, tell the clinician if you take more than prescribed or use it for another purpose. The response should address the actual problem rather than rely on a label alone.

Suboxone films and Zubsolv tablets have different formulation characteristics. Their printed strengths are not a simple one-for-one substitution rule. EMA specifically notes that Zubsolv and its reference product cannot be treated as interchangeable without the appropriate prescribing decision. Check any change with the clinician and pharmacist. [2]

Follow the exact instructions for where the medicine dissolves. Do not chew, swallow whole, cut or otherwise alter a product unless its own instructions explicitly permit the method and the prescriber has explained it. If the technique is difficult, ask for a demonstration rather than quietly changing how you take it. A product review can consider practical suitability without leaving you to improvise.

Buprenorphine products dissolved in the mouth can be associated with dental decay, infection, fracture and tooth loss. FDA emphasizes that their benefits in treating opioid use disorder outweigh these risks, so dental concerns should prompt prevention and care rather than abrupt discontinuation. [6]

After the medicine has fully dissolved, gently rinse the teeth and gums with water and swallow it, and wait at least one hour before brushing. Arrange regular dental review and report pain or changes promptly. Tell the dentist about the treatment. Ask the prescribing team and dentist to coordinate when a dental problem makes using the medicine difficult. [6]

Alcohol, benzodiazepines, gabapentin, pregabalin and other central nervous system depressants can increase sedation and breathing risks. Tell the team about all such use, including legitimate prescriptions from another service. Severe drowsiness, slurred speech with marked impairment or slowed breathing requires prompt assessment; inability to wake or breathing difficulty is an emergency. [3]

Do not conceal substances or abruptly stop another dependence-forming medicine to avoid a difficult interaction discussion. Ask the clinicians to agree a coordinated plan. The purpose is to improve safety while preserving effective treatment where appropriate. Having naloxone in the combination is not protection against these risks.

Constipation, headache, sweating, nausea, sleep problems and mouth discomfort can occur. Persistent symptoms deserve review rather than being treated as a test of commitment to recovery. Yellowing skin or eyes, dark urine or significant upper abdominal pain can indicate liver problems and needs prompt medical advice. [4]

Ask what tests are appropriate and who will review them. Describe the effect on daily life: difficulty eating, working or sleeping can help the clinician understand the burden. Do not add remedies or alter the prescription independently. Some symptoms may have another cause, and severe illness should not wait for a routine medication appointment.

The combination’s established role is opioid treatment, not routine treatment of depression, anxiety, bipolar disorder or trauma. Those concerns need their own assessment. Improved opioid stability does not prove that all mental health needs have been met, and a return of distress should not automatically be interpreted as inadequate opioid dosing.

Ask who coordinates psychological care and psychiatric prescriptions with the opioid-treatment plan. Describe mood, sleep and substance use over time. Immediate suicidal danger or inability to remain safe requires emergency help. Our co-occurring-needs overview explains the wider assessment without selecting a medication or guaranteeing a particular detox service.

Tell dentists, surgeons and emergency clinicians about the exact combination product and dose schedule before a procedure. Do not stop it or take extra opioid pain medicine independently to prepare for surgery. Pain management and continuity of opioid treatment need one coordinated plan rather than separate instructions that conflict.

Pregnancy or breastfeeding also needs specialist discussion. Do not abruptly stop established treatment because pregnancy is discovered. The care team should consider maternal treatment, the appropriate product and assessment of the baby, including possible neonatal withdrawal. A webpage cannot select between single-ingredient and combination products for your situation. [3]

Abrupt discontinuation can cause opioid withdrawal. If a reduction is appropriate, the clinician should plan it with continuing review of symptoms and return-to-use risk. Do not double a missed dose or restart an old regimen after a substantial interruption without advice. [4]

After a period without opioids, tolerance may be reduced, making a return to a previous amount dangerous. Discuss rescue medication and a route back to treatment before stopping. A taper is not a complete recovery plan on its own. Ask what support remains if cravings return or a reduction becomes difficult, rather than waiting for a crisis to seek help. [5]

Keep the medicine in its labeled packaging in a secure place away from children and anyone for whom it was not prescribed. Accidental ingestion by a child is an emergency. Never share tablets or films, including with someone who says they have the same symptoms. Ask a pharmacist about safe disposal and travel arrangements. [3]

Make rescue naloxone accessible to someone who may need to use it while keeping the opioid-treatment medicine secured. These are different storage priorities. Review the plan when moving home, traveling or changing treatment services. A clear handover should include the formulation, last dose, response and any unresolved concerns.

Is the naloxone component an overdose antidote I can rely on?

No. A separate rescue product and emergency response are still needed for suspected overdose.

Can I switch between Suboxone and Zubsolv myself?

No. Formulations and exposure differ. A prescriber should direct the switch.

What should I bring to a review?

Bring the actual packet, dosing history, other medicines and substances, side effects and questions about continuing treatment. The medication-review checklist can help organize the discussion.

1. EMA: Suboxone.
2. EMA: Zubsolv and formulation differences.
3. Manufacturer: Suboxone indications and safety information.
4. MedlinePlus: Buprenorphine and buprenorphine-naloxone.
5. CDC: Opioid use disorder treatment.
6. FDA: Dental precautions with buprenorphine.

Educational information only. Local product information and the clinical team determine treatment. Inclusion is not a promise of prescribing or detoxification at COGNIFUL. Return to the medication library.